NLRP3 and gout: OLT1177 (Dapansutrile): In human trials for acute heart failure and gout, an oral NLRP3 inhibitor has shown a good safety profile. It successfully decreases infarct size in MIRI models, according to preclinical evidence [32]. One of the most sophisticated NLRP3 inhibitors as of 2025, it represents a direct translational avenue for this target and has active plans for phase II trials in acute myocardial infarction.